MedPath

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

Phase 4
Active, not recruiting
Conditions
Peyronie's Disease
Interventions
Procedure: Penile Plication Surgery
Device: RestoreX Penile Traction Device
Procedure: Incision and Grafting (I&G) Surgery
Registration Number
NCT04786106
Lead Sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Brief Summary

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

Detailed Description

After eligible patients have been informed about the study protocol and risks and consent have been given, men will be randomly assigned into either the collagenase clostridium histolyticum + penile traction therapy (CCH + PTT) group or to the surgery + penile traction therapy (surgery + PTT) group. Those in the CCH + PTT group will receive the full 4 series of 8 Xiaflex injections with 1-3 days between each set of 2 injections and 6 weeks prior to the next series. Patients would then use the RestoreX traction device throughout the series to 3 months post-treatment. Those that were assigned the surgery + PTT treatment protocol would undergo surgery using either penile plication or incision and grafting, depending on the degree of curvature and erectile function. Traction using RestoreX will also be prescribed to these men 2-4 weeks post-operatively until 3 months post-treatment. Key clinical outcomes of both treatment protocols will be compared.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Male
Target Recruitment
40
Inclusion Criteria
  • Men with PD
  • >18 years old
  • Curvature ≥30 degrees
  • Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors
Exclusion Criteria
  • Prior treatment with CCH or surgery
  • Moderate (shadowing) or severe (>1 cm) penile calcification
  • Any contraindications to CCH, PTT, or surgery - as determined by the PI

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CCH+PTTRestoreX Penile Traction DeviceMen will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
Surgery+PTTPenile Plication SurgeryMen will undergo either penile plication or I\&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
Surgery+PTTIncision and Grafting (I&G) SurgeryMen will undergo either penile plication or I\&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
Surgery+PTTRestoreX Penile Traction DeviceMen will undergo either penile plication or I\&G based on appropriate clinical criteria for either surgery. 2-4 weeks post-operatively (depending on tolerability), the patients will be asked to perform PTT 30-60 minutes daily until the 3-month post-treatment visit.
CCH+PTTCollagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)Men will receive two injections of CCH administered 1-3 days apart, followed by manual modeling and PTT 30-60 min/day as outlined in our prior publication. Approximately 6 weeks later, the next round of injections will be performed until a maximum of 8 injections in total has been administered. PTT will be continued until the 3-month post-treatment visit.
Primary Outcome Measures
NameTimeMethod
Subjective reporting of erectile dysfunction post treatment1 year

Comparison of erectile dysfunction complication rates

Overall satisfaction with treatment1 year

Answer to SAPS question #1 (How satisfied are you with the effect of your treatment?) to determine overall satisfaction at all time points

Subjective reporting of changes in penile length post treatment1 year

Comparison of perceived changes in penile length complication rates

International Index of Erectile Function, Erectile Function Domain (IIEF) Scores1 year

Comparison of IIEF erectile function domain score (Q1-5, 15; min/max 1-30; higher is better)

Subjective reporting of changes in penile sensation post treatment1 year

Comparison of changes in penile sensation complication rates

Secondary Outcome Measures
NameTimeMethod
Peyronie's Disease Questionnaire (PDQ) Scores1 year

Comparison of PDQ questionnaire scores; Subdomains - psychological and physical (Q1-6; min/max 0-24; lower is better), penile pain (Q7-9; min/max 0-30; lower is better), symptom bother (Q10-15; min/max 0-16; lower is better)

International Index of Erectile Function (IIEF) Scores1 year

Comparison of IIEF questionnaire scores-all domains except erectile function (which is a primary endpoint); subdomains: orgasmic function (Q9-10; min/max 0-10; higher is better), sexual desire (Q11-12; min/max 2-10; higher is better), intercourse satisfaction (Q6-8; min/max 0-15; higher is better), overall satisfaction (Q13-14; min/max 2-10; higher is better)

Beck's Depression Inventory (BDI) Scores1 year

Comparison of BDI questionnaire scores on depression. 21 items (min/max 0-63, lower is better)

Penile Curvature1 year

Comparison of changes in penile curvature

Objective measurements of penile length post treatment (compared to pre-treatment)1 year

Comparison of changes in penile length

Interventions required1 year

Comparison of subsequent interventions required - surgery or CCH injections

Hospitalizations1 year

Number of hospitalizations or ER visits resulting from treatment

Non-standardized questionnaire1 year

Comparison of non-standardized questionnaire responses

Trial Locations

Locations (1)

The Male Fertility and Peyronie's Clinic

🇺🇸

Orem, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath